nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—PTGS2—atherosclerosis	0.247	1	CbGaD
Etoricoxib—CYP2C19—Rosuvastatin—atherosclerosis	0.0391	0.089	CbGbCtD
Etoricoxib—CYP2C19—Simvastatin—atherosclerosis	0.0364	0.0827	CbGbCtD
Etoricoxib—CYP2C19—Lovastatin—atherosclerosis	0.0356	0.081	CbGbCtD
Etoricoxib—CYP2D6—Niacin—atherosclerosis	0.035	0.0796	CbGbCtD
Etoricoxib—CYP2C9—Rosuvastatin—atherosclerosis	0.0325	0.074	CbGbCtD
Etoricoxib—CYP2C9—Simvastatin—atherosclerosis	0.0303	0.0688	CbGbCtD
Etoricoxib—CYP2C9—Pravastatin—atherosclerosis	0.0296	0.0673	CbGbCtD
Etoricoxib—CYP2C9—Lovastatin—atherosclerosis	0.0296	0.0673	CbGbCtD
Etoricoxib—CYP2D6—Simvastatin—atherosclerosis	0.0277	0.0629	CbGbCtD
Etoricoxib—CYP2D6—Lovastatin—atherosclerosis	0.0271	0.0616	CbGbCtD
Etoricoxib—CYP2D6—Pravastatin—atherosclerosis	0.0271	0.0616	CbGbCtD
Etoricoxib—CYP3A4—Ezetimibe—atherosclerosis	0.0189	0.043	CbGbCtD
Etoricoxib—CYP3A4—Rosuvastatin—atherosclerosis	0.0189	0.043	CbGbCtD
Etoricoxib—CYP3A4—Simvastatin—atherosclerosis	0.0176	0.04	CbGbCtD
Etoricoxib—CYP3A4—Lovastatin—atherosclerosis	0.0172	0.0391	CbGbCtD
Etoricoxib—CYP3A4—Pravastatin—atherosclerosis	0.0172	0.0391	CbGbCtD
Etoricoxib—MAPK14—blood vessel—atherosclerosis	0.00222	0.15	CbGeAlD
Etoricoxib—PTGS2—leg—atherosclerosis	0.00149	0.101	CbGeAlD
Etoricoxib—PTGS2—hindlimb—atherosclerosis	0.00133	0.0903	CbGeAlD
Etoricoxib—PTGS2—appendage—atherosclerosis	0.00114	0.0774	CbGeAlD
Etoricoxib—MAPK14—connective tissue—atherosclerosis	0.00114	0.0769	CbGeAlD
Etoricoxib—Vemurafenib—ALB—atherosclerosis	0.001	0.364	CrCbGaD
Etoricoxib—MAPK14—cardiovascular system—atherosclerosis	0.000989	0.0669	CbGeAlD
Etoricoxib—MAPK14—adipose tissue—atherosclerosis	0.000872	0.059	CbGeAlD
Etoricoxib—PTGS2—artery—atherosclerosis	0.000818	0.0553	CbGeAlD
Etoricoxib—PTGS2—endothelium—atherosclerosis	0.000691	0.0467	CbGeAlD
Etoricoxib—Celecoxib—PTGS2—atherosclerosis	0.00066	0.24	CrCbGaD
Etoricoxib—PTGS2—blood vessel—atherosclerosis	0.000637	0.0431	CbGeAlD
Etoricoxib—MAPK14—liver—atherosclerosis	0.000611	0.0414	CbGeAlD
Etoricoxib—Celecoxib—ALB—atherosclerosis	0.000588	0.214	CrCbGaD
Etoricoxib—Vismodegib—ALB—atherosclerosis	0.000504	0.183	CrCbGaD
Etoricoxib—Erythema multiforme—Simvastatin—atherosclerosis	0.000363	0.00211	CcSEcCtD
Etoricoxib—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000363	0.0021	CcSEcCtD
Etoricoxib—Sinusitis—Pravastatin—atherosclerosis	0.000363	0.0021	CcSEcCtD
Etoricoxib—Alopecia—Lovastatin—atherosclerosis	0.000363	0.0021	CcSEcCtD
Etoricoxib—Arthralgia—Rosuvastatin—atherosclerosis	0.000359	0.00208	CcSEcCtD
Etoricoxib—Flushing—Simvastatin—atherosclerosis	0.000356	0.00207	CcSEcCtD
Etoricoxib—Alopecia—Ezetimibe—atherosclerosis	0.000356	0.00206	CcSEcCtD
Etoricoxib—Haemoglobin—Niacin—atherosclerosis	0.000354	0.00206	CcSEcCtD
Etoricoxib—Mental disorder—Ezetimibe—atherosclerosis	0.000353	0.00205	CcSEcCtD
Etoricoxib—Hepatitis—Niacin—atherosclerosis	0.000353	0.00205	CcSEcCtD
Etoricoxib—Haemorrhage—Niacin—atherosclerosis	0.000353	0.00205	CcSEcCtD
Etoricoxib—Flatulence—Lovastatin—atherosclerosis	0.000352	0.00204	CcSEcCtD
Etoricoxib—Hypoaesthesia—Niacin—atherosclerosis	0.000351	0.00203	CcSEcCtD
Etoricoxib—Malnutrition—Ezetimibe—atherosclerosis	0.00035	0.00203	CcSEcCtD
Etoricoxib—Erythema—Ezetimibe—atherosclerosis	0.00035	0.00203	CcSEcCtD
Etoricoxib—Dysgeusia—Lovastatin—atherosclerosis	0.00035	0.00203	CcSEcCtD
Etoricoxib—Oedema peripheral—Niacin—atherosclerosis	0.000347	0.00201	CcSEcCtD
Etoricoxib—Hepatitis—Pravastatin—atherosclerosis	0.000347	0.00201	CcSEcCtD
Etoricoxib—Confusional state—Rosuvastatin—atherosclerosis	0.000347	0.00201	CcSEcCtD
Etoricoxib—Hypoaesthesia—Pravastatin—atherosclerosis	0.000345	0.002	CcSEcCtD
Etoricoxib—Flatulence—Ezetimibe—atherosclerosis	0.000345	0.002	CcSEcCtD
Etoricoxib—Pharyngitis—Pravastatin—atherosclerosis	0.000345	0.002	CcSEcCtD
Etoricoxib—Muscle spasms—Lovastatin—atherosclerosis	0.000344	0.00199	CcSEcCtD
Etoricoxib—Infection—Rosuvastatin—atherosclerosis	0.000342	0.00198	CcSEcCtD
Etoricoxib—Visual impairment—Niacin—atherosclerosis	0.00034	0.00197	CcSEcCtD
Etoricoxib—Alopecia—Simvastatin—atherosclerosis	0.000339	0.00197	CcSEcCtD
Etoricoxib—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000337	0.00196	CcSEcCtD
Etoricoxib—Muscle spasms—Ezetimibe—atherosclerosis	0.000337	0.00195	CcSEcCtD
Etoricoxib—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000337	0.00195	CcSEcCtD
Etoricoxib—Vision blurred—Lovastatin—atherosclerosis	0.000337	0.00195	CcSEcCtD
Etoricoxib—Mental disorder—Simvastatin—atherosclerosis	0.000336	0.00195	CcSEcCtD
Etoricoxib—Tremor—Lovastatin—atherosclerosis	0.000335	0.00194	CcSEcCtD
Etoricoxib—Visual impairment—Pravastatin—atherosclerosis	0.000335	0.00194	CcSEcCtD
Etoricoxib—Erythema—Simvastatin—atherosclerosis	0.000334	0.00194	CcSEcCtD
Etoricoxib—Eye disorder—Niacin—atherosclerosis	0.000329	0.00191	CcSEcCtD
Etoricoxib—Flatulence—Simvastatin—atherosclerosis	0.000329	0.00191	CcSEcCtD
Etoricoxib—Tinnitus—Niacin—atherosclerosis	0.000329	0.00191	CcSEcCtD
Etoricoxib—Erythema multiforme—Pravastatin—atherosclerosis	0.000328	0.0019	CcSEcCtD
Etoricoxib—Dysgeusia—Simvastatin—atherosclerosis	0.000327	0.0019	CcSEcCtD
Etoricoxib—Flushing—Niacin—atherosclerosis	0.000327	0.0019	CcSEcCtD
Etoricoxib—PTGS2—connective tissue—atherosclerosis	0.000327	0.0221	CbGeAlD
Etoricoxib—Angioedema—Lovastatin—atherosclerosis	0.000327	0.00189	CcSEcCtD
Etoricoxib—CYP2C9—cardiovascular system—atherosclerosis	0.000326	0.022	CbGeAlD
Etoricoxib—Anaemia—Ezetimibe—atherosclerosis	0.000324	0.00188	CcSEcCtD
Etoricoxib—Tinnitus—Pravastatin—atherosclerosis	0.000324	0.00188	CcSEcCtD
Etoricoxib—Cardiac disorder—Pravastatin—atherosclerosis	0.000322	0.00187	CcSEcCtD
Etoricoxib—Flushing—Pravastatin—atherosclerosis	0.000322	0.00187	CcSEcCtD
Etoricoxib—Muscle spasms—Simvastatin—atherosclerosis	0.000321	0.00186	CcSEcCtD
Etoricoxib—Angioedema—Ezetimibe—atherosclerosis	0.00032	0.00186	CcSEcCtD
Etoricoxib—Angiopathy—Niacin—atherosclerosis	0.00032	0.00186	CcSEcCtD
Etoricoxib—Vision blurred—Simvastatin—atherosclerosis	0.000315	0.00183	CcSEcCtD
Etoricoxib—Arrhythmia—Niacin—atherosclerosis	0.000315	0.00183	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000314	0.00182	CcSEcCtD
Etoricoxib—Tremor—Simvastatin—atherosclerosis	0.000313	0.00182	CcSEcCtD
Etoricoxib—Alopecia—Niacin—atherosclerosis	0.000312	0.00181	CcSEcCtD
Etoricoxib—Insomnia—Rosuvastatin—atherosclerosis	0.000311	0.00181	CcSEcCtD
Etoricoxib—Arrhythmia—Pravastatin—atherosclerosis	0.00031	0.0018	CcSEcCtD
Etoricoxib—Palpitations—Ezetimibe—atherosclerosis	0.00031	0.0018	CcSEcCtD
Etoricoxib—Anaemia—Simvastatin—atherosclerosis	0.000309	0.00179	CcSEcCtD
Etoricoxib—CYP2E1—cardiovascular system—atherosclerosis	0.000309	0.0209	CbGeAlD
Etoricoxib—Erythema—Niacin—atherosclerosis	0.000307	0.00178	CcSEcCtD
Etoricoxib—Malnutrition—Niacin—atherosclerosis	0.000307	0.00178	CcSEcCtD
Etoricoxib—Alopecia—Pravastatin—atherosclerosis	0.000307	0.00178	CcSEcCtD
Etoricoxib—Cough—Ezetimibe—atherosclerosis	0.000306	0.00177	CcSEcCtD
Etoricoxib—Angioedema—Simvastatin—atherosclerosis	0.000305	0.00177	CcSEcCtD
Etoricoxib—Arthralgia—Lovastatin—atherosclerosis	0.000304	0.00176	CcSEcCtD
Etoricoxib—Chest pain—Lovastatin—atherosclerosis	0.000304	0.00176	CcSEcCtD
Etoricoxib—Anxiety—Lovastatin—atherosclerosis	0.000303	0.00176	CcSEcCtD
Etoricoxib—Dyspepsia—Rosuvastatin—atherosclerosis	0.000303	0.00176	CcSEcCtD
Etoricoxib—Hypertension—Ezetimibe—atherosclerosis	0.000303	0.00176	CcSEcCtD
Etoricoxib—Flatulence—Niacin—atherosclerosis	0.000302	0.00175	CcSEcCtD
Etoricoxib—Arthralgia—Ezetimibe—atherosclerosis	0.000298	0.00173	CcSEcCtD
Etoricoxib—Chest pain—Ezetimibe—atherosclerosis	0.000298	0.00173	CcSEcCtD
Etoricoxib—Flatulence—Pravastatin—atherosclerosis	0.000298	0.00173	CcSEcCtD
Etoricoxib—Dry mouth—Lovastatin—atherosclerosis	0.000298	0.00173	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000296	0.00172	CcSEcCtD
Etoricoxib—Dysgeusia—Pravastatin—atherosclerosis	0.000296	0.00172	CcSEcCtD
Etoricoxib—Muscle spasms—Niacin—atherosclerosis	0.000295	0.00171	CcSEcCtD
Etoricoxib—Constipation—Rosuvastatin—atherosclerosis	0.000294	0.00171	CcSEcCtD
Etoricoxib—Pain—Rosuvastatin—atherosclerosis	0.000294	0.00171	CcSEcCtD
Etoricoxib—Confusional state—Lovastatin—atherosclerosis	0.000294	0.00171	CcSEcCtD
Etoricoxib—Dry mouth—Ezetimibe—atherosclerosis	0.000292	0.00169	CcSEcCtD
Etoricoxib—Anaphylactic shock—Lovastatin—atherosclerosis	0.000292	0.00169	CcSEcCtD
Etoricoxib—Muscle spasms—Pravastatin—atherosclerosis	0.000291	0.00169	CcSEcCtD
Etoricoxib—Infection—Lovastatin—atherosclerosis	0.00029	0.00168	CcSEcCtD
Etoricoxib—Vision blurred—Niacin—atherosclerosis	0.000289	0.00168	CcSEcCtD
Etoricoxib—Confusional state—Ezetimibe—atherosclerosis	0.000288	0.00167	CcSEcCtD
Etoricoxib—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000286	0.00166	CcSEcCtD
Etoricoxib—Thrombocytopenia—Lovastatin—atherosclerosis	0.000286	0.00166	CcSEcCtD
Etoricoxib—Vision blurred—Pravastatin—atherosclerosis	0.000285	0.00165	CcSEcCtD
Etoricoxib—Chest pain—Simvastatin—atherosclerosis	0.000285	0.00165	CcSEcCtD
Etoricoxib—Arthralgia—Simvastatin—atherosclerosis	0.000285	0.00165	CcSEcCtD
Etoricoxib—PTGS2—cardiovascular system—atherosclerosis	0.000284	0.0192	CbGeAlD
Etoricoxib—Infection—Ezetimibe—atherosclerosis	0.000284	0.00165	CcSEcCtD
Etoricoxib—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000284	0.00165	CcSEcCtD
Etoricoxib—Anxiety—Simvastatin—atherosclerosis	0.000284	0.00165	CcSEcCtD
Etoricoxib—Tremor—Pravastatin—atherosclerosis	0.000283	0.00164	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000281	0.00163	CcSEcCtD
Etoricoxib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000281	0.00163	CcSEcCtD
Etoricoxib—Angioedema—Niacin—atherosclerosis	0.00028	0.00163	CcSEcCtD
Etoricoxib—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00028	0.00162	CcSEcCtD
Etoricoxib—Anaemia—Pravastatin—atherosclerosis	0.000279	0.00162	CcSEcCtD
Etoricoxib—Anorexia—Lovastatin—atherosclerosis	0.000278	0.00161	CcSEcCtD
Etoricoxib—Skin disorder—Ezetimibe—atherosclerosis	0.000278	0.00161	CcSEcCtD
Etoricoxib—Angioedema—Pravastatin—atherosclerosis	0.000276	0.0016	CcSEcCtD
Etoricoxib—Confusional state—Simvastatin—atherosclerosis	0.000275	0.0016	CcSEcCtD
Etoricoxib—Urticaria—Rosuvastatin—atherosclerosis	0.000273	0.00159	CcSEcCtD
Etoricoxib—Oedema—Simvastatin—atherosclerosis	0.000273	0.00158	CcSEcCtD
Etoricoxib—Anaphylactic shock—Simvastatin—atherosclerosis	0.000273	0.00158	CcSEcCtD
Etoricoxib—Abdominal pain—Rosuvastatin—atherosclerosis	0.000272	0.00158	CcSEcCtD
Etoricoxib—Palpitations—Niacin—atherosclerosis	0.000271	0.00157	CcSEcCtD
Etoricoxib—Infection—Simvastatin—atherosclerosis	0.000271	0.00157	CcSEcCtD
Etoricoxib—Cough—Niacin—atherosclerosis	0.000268	0.00155	CcSEcCtD
Etoricoxib—Thrombocytopenia—Simvastatin—atherosclerosis	0.000267	0.00155	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000266	0.00154	CcSEcCtD
Etoricoxib—Insomnia—Lovastatin—atherosclerosis	0.000264	0.00153	CcSEcCtD
Etoricoxib—Cough—Pravastatin—atherosclerosis	0.000264	0.00153	CcSEcCtD
Etoricoxib—Arthralgia—Niacin—atherosclerosis	0.000261	0.00152	CcSEcCtD
Etoricoxib—Hypertension—Pravastatin—atherosclerosis	0.000261	0.00151	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000261	0.00151	CcSEcCtD
Etoricoxib—Anorexia—Simvastatin—atherosclerosis	0.00026	0.00151	CcSEcCtD
Etoricoxib—Dyspnoea—Lovastatin—atherosclerosis	0.00026	0.00151	CcSEcCtD
Etoricoxib—CYP2C19—liver—atherosclerosis	0.00026	0.0176	CbGeAlD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000259	0.00151	CcSEcCtD
Etoricoxib—Insomnia—Ezetimibe—atherosclerosis	0.000259	0.0015	CcSEcCtD
Etoricoxib—Chest pain—Pravastatin—atherosclerosis	0.000257	0.00149	CcSEcCtD
Etoricoxib—Arthralgia—Pravastatin—atherosclerosis	0.000257	0.00149	CcSEcCtD
Etoricoxib—Dyspepsia—Lovastatin—atherosclerosis	0.000257	0.00149	CcSEcCtD
Etoricoxib—Anxiety—Pravastatin—atherosclerosis	0.000256	0.00149	CcSEcCtD
Etoricoxib—Dry mouth—Niacin—atherosclerosis	0.000256	0.00148	CcSEcCtD
Etoricoxib—Dyspnoea—Ezetimibe—atherosclerosis	0.000255	0.00148	CcSEcCtD
Etoricoxib—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000254	0.00147	CcSEcCtD
Etoricoxib—Decreased appetite—Lovastatin—atherosclerosis	0.000254	0.00147	CcSEcCtD
Etoricoxib—Dyspepsia—Ezetimibe—atherosclerosis	0.000252	0.00146	CcSEcCtD
Etoricoxib—Fatigue—Lovastatin—atherosclerosis	0.000251	0.00146	CcSEcCtD
Etoricoxib—PTGS2—adipose tissue—atherosclerosis	0.000251	0.017	CbGeAlD
Etoricoxib—Oedema—Niacin—atherosclerosis	0.00025	0.00145	CcSEcCtD
Etoricoxib—Anaphylactic shock—Niacin—atherosclerosis	0.00025	0.00145	CcSEcCtD
Etoricoxib—Constipation—Lovastatin—atherosclerosis	0.000249	0.00145	CcSEcCtD
Etoricoxib—Pain—Lovastatin—atherosclerosis	0.000249	0.00145	CcSEcCtD
Etoricoxib—Confusional state—Pravastatin—atherosclerosis	0.000249	0.00144	CcSEcCtD
Etoricoxib—Decreased appetite—Ezetimibe—atherosclerosis	0.000249	0.00144	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000249	0.00144	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000247	0.00143	CcSEcCtD
Etoricoxib—Asthenia—Rosuvastatin—atherosclerosis	0.000247	0.00143	CcSEcCtD
Etoricoxib—Insomnia—Simvastatin—atherosclerosis	0.000247	0.00143	CcSEcCtD
Etoricoxib—Anaphylactic shock—Pravastatin—atherosclerosis	0.000247	0.00143	CcSEcCtD
Etoricoxib—Oedema—Pravastatin—atherosclerosis	0.000247	0.00143	CcSEcCtD
Etoricoxib—Fatigue—Ezetimibe—atherosclerosis	0.000247	0.00143	CcSEcCtD
Etoricoxib—Shock—Niacin—atherosclerosis	0.000246	0.00143	CcSEcCtD
Etoricoxib—Infection—Pravastatin—atherosclerosis	0.000245	0.00142	CcSEcCtD
Etoricoxib—Constipation—Ezetimibe—atherosclerosis	0.000245	0.00142	CcSEcCtD
Etoricoxib—Pain—Ezetimibe—atherosclerosis	0.000245	0.00142	CcSEcCtD
Etoricoxib—Pruritus—Rosuvastatin—atherosclerosis	0.000243	0.00141	CcSEcCtD
Etoricoxib—Skin disorder—Niacin—atherosclerosis	0.000243	0.00141	CcSEcCtD
Etoricoxib—Dyspnoea—Simvastatin—atherosclerosis	0.000243	0.00141	CcSEcCtD
Etoricoxib—Thrombocytopenia—Pravastatin—atherosclerosis	0.000241	0.0014	CcSEcCtD
Etoricoxib—Feeling abnormal—Lovastatin—atherosclerosis	0.00024	0.00139	CcSEcCtD
Etoricoxib—Dyspepsia—Simvastatin—atherosclerosis	0.00024	0.00139	CcSEcCtD
Etoricoxib—Anorexia—Niacin—atherosclerosis	0.000239	0.00139	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000238	0.00138	CcSEcCtD
Etoricoxib—Decreased appetite—Simvastatin—atherosclerosis	0.000237	0.00138	CcSEcCtD
Etoricoxib—Feeling abnormal—Ezetimibe—atherosclerosis	0.000236	0.00137	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000236	0.00137	CcSEcCtD
Etoricoxib—Diarrhoea—Rosuvastatin—atherosclerosis	0.000235	0.00137	CcSEcCtD
Etoricoxib—Fatigue—Simvastatin—atherosclerosis	0.000235	0.00136	CcSEcCtD
Etoricoxib—Anorexia—Pravastatin—atherosclerosis	0.000235	0.00136	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000234	0.00136	CcSEcCtD
Etoricoxib—Pain—Simvastatin—atherosclerosis	0.000233	0.00135	CcSEcCtD
Etoricoxib—Constipation—Simvastatin—atherosclerosis	0.000233	0.00135	CcSEcCtD
Etoricoxib—Urticaria—Lovastatin—atherosclerosis	0.000232	0.00134	CcSEcCtD
Etoricoxib—Abdominal pain—Lovastatin—atherosclerosis	0.000231	0.00134	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000228	0.00132	CcSEcCtD
Etoricoxib—Dizziness—Rosuvastatin—atherosclerosis	0.000228	0.00132	CcSEcCtD
Etoricoxib—Urticaria—Ezetimibe—atherosclerosis	0.000227	0.00132	CcSEcCtD
Etoricoxib—Insomnia—Niacin—atherosclerosis	0.000227	0.00131	CcSEcCtD
Etoricoxib—Abdominal pain—Ezetimibe—atherosclerosis	0.000226	0.00131	CcSEcCtD
Etoricoxib—Feeling abnormal—Simvastatin—atherosclerosis	0.000225	0.0013	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000225	0.0013	CcSEcCtD
Etoricoxib—Dyspnoea—Niacin—atherosclerosis	0.000223	0.0013	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000223	0.00129	CcSEcCtD
Etoricoxib—Insomnia—Pravastatin—atherosclerosis	0.000223	0.00129	CcSEcCtD
Etoricoxib—Somnolence—Niacin—atherosclerosis	0.000223	0.00129	CcSEcCtD
Etoricoxib—Dyspepsia—Niacin—atherosclerosis	0.00022	0.00128	CcSEcCtD
Etoricoxib—Dyspnoea—Pravastatin—atherosclerosis	0.00022	0.00128	CcSEcCtD
Etoricoxib—Decreased appetite—Niacin—atherosclerosis	0.000218	0.00126	CcSEcCtD
Etoricoxib—Dyspepsia—Pravastatin—atherosclerosis	0.000217	0.00126	CcSEcCtD
Etoricoxib—Rash—Rosuvastatin—atherosclerosis	0.000217	0.00126	CcSEcCtD
Etoricoxib—Dermatitis—Rosuvastatin—atherosclerosis	0.000217	0.00126	CcSEcCtD
Etoricoxib—Urticaria—Simvastatin—atherosclerosis	0.000217	0.00126	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Niacin—atherosclerosis	0.000216	0.00125	CcSEcCtD
Etoricoxib—Abdominal pain—Simvastatin—atherosclerosis	0.000216	0.00125	CcSEcCtD
Etoricoxib—Headache—Rosuvastatin—atherosclerosis	0.000216	0.00125	CcSEcCtD
Etoricoxib—Hypersensitivity—Lovastatin—atherosclerosis	0.000215	0.00125	CcSEcCtD
Etoricoxib—Decreased appetite—Pravastatin—atherosclerosis	0.000214	0.00124	CcSEcCtD
Etoricoxib—Pain—Niacin—atherosclerosis	0.000214	0.00124	CcSEcCtD
Etoricoxib—Fatigue—Pravastatin—atherosclerosis	0.000213	0.00123	CcSEcCtD
Etoricoxib—CYP1A2—liver—atherosclerosis	0.000212	0.0144	CbGeAlD
Etoricoxib—Pain—Pravastatin—atherosclerosis	0.000211	0.00122	CcSEcCtD
Etoricoxib—Constipation—Pravastatin—atherosclerosis	0.000211	0.00122	CcSEcCtD
Etoricoxib—Hypersensitivity—Ezetimibe—atherosclerosis	0.000211	0.00122	CcSEcCtD
Etoricoxib—Asthenia—Lovastatin—atherosclerosis	0.000209	0.00121	CcSEcCtD
Etoricoxib—Pruritus—Lovastatin—atherosclerosis	0.000206	0.0012	CcSEcCtD
Etoricoxib—Asthenia—Ezetimibe—atherosclerosis	0.000205	0.00119	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Niacin—atherosclerosis	0.000205	0.00119	CcSEcCtD
Etoricoxib—Nausea—Rosuvastatin—atherosclerosis	0.000204	0.00119	CcSEcCtD
Etoricoxib—Feeling abnormal—Pravastatin—atherosclerosis	0.000203	0.00118	CcSEcCtD
Etoricoxib—Pruritus—Ezetimibe—atherosclerosis	0.000202	0.00117	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000202	0.00117	CcSEcCtD
Etoricoxib—CYP2C9—liver—atherosclerosis	0.000201	0.0136	CbGeAlD
Etoricoxib—Hypersensitivity—Simvastatin—atherosclerosis	0.000201	0.00117	CcSEcCtD
Etoricoxib—Diarrhoea—Lovastatin—atherosclerosis	0.0002	0.00116	CcSEcCtD
Etoricoxib—Urticaria—Niacin—atherosclerosis	0.000199	0.00115	CcSEcCtD
Etoricoxib—Abdominal pain—Niacin—atherosclerosis	0.000198	0.00115	CcSEcCtD
Etoricoxib—Urticaria—Pravastatin—atherosclerosis	0.000196	0.00114	CcSEcCtD
Etoricoxib—Asthenia—Simvastatin—atherosclerosis	0.000196	0.00114	CcSEcCtD
Etoricoxib—Diarrhoea—Ezetimibe—atherosclerosis	0.000196	0.00114	CcSEcCtD
Etoricoxib—Abdominal pain—Pravastatin—atherosclerosis	0.000195	0.00113	CcSEcCtD
Etoricoxib—Pruritus—Simvastatin—atherosclerosis	0.000193	0.00112	CcSEcCtD
Etoricoxib—Dizziness—Lovastatin—atherosclerosis	0.000193	0.00112	CcSEcCtD
Etoricoxib—CYP2E1—liver—atherosclerosis	0.000191	0.0129	CbGeAlD
Etoricoxib—Dizziness—Ezetimibe—atherosclerosis	0.000189	0.0011	CcSEcCtD
Etoricoxib—Diarrhoea—Simvastatin—atherosclerosis	0.000187	0.00108	CcSEcCtD
Etoricoxib—Vomiting—Lovastatin—atherosclerosis	0.000185	0.00108	CcSEcCtD
Etoricoxib—Hypersensitivity—Niacin—atherosclerosis	0.000185	0.00107	CcSEcCtD
Etoricoxib—Rash—Lovastatin—atherosclerosis	0.000184	0.00107	CcSEcCtD
Etoricoxib—Dermatitis—Lovastatin—atherosclerosis	0.000184	0.00107	CcSEcCtD
Etoricoxib—Headache—Lovastatin—atherosclerosis	0.000183	0.00106	CcSEcCtD
Etoricoxib—Vomiting—Ezetimibe—atherosclerosis	0.000182	0.00106	CcSEcCtD
Etoricoxib—Hypersensitivity—Pravastatin—atherosclerosis	0.000182	0.00105	CcSEcCtD
Etoricoxib—Dizziness—Simvastatin—atherosclerosis	0.00018	0.00105	CcSEcCtD
Etoricoxib—Rash—Ezetimibe—atherosclerosis	0.00018	0.00105	CcSEcCtD
Etoricoxib—Dermatitis—Ezetimibe—atherosclerosis	0.00018	0.00105	CcSEcCtD
Etoricoxib—Asthenia—Niacin—atherosclerosis	0.00018	0.00104	CcSEcCtD
Etoricoxib—Headache—Ezetimibe—atherosclerosis	0.000179	0.00104	CcSEcCtD
Etoricoxib—Pruritus—Niacin—atherosclerosis	0.000177	0.00103	CcSEcCtD
Etoricoxib—Asthenia—Pravastatin—atherosclerosis	0.000177	0.00103	CcSEcCtD
Etoricoxib—PTGS2—liver—atherosclerosis	0.000176	0.0119	CbGeAlD
Etoricoxib—Pruritus—Pravastatin—atherosclerosis	0.000174	0.00101	CcSEcCtD
Etoricoxib—Vomiting—Simvastatin—atherosclerosis	0.000173	0.00101	CcSEcCtD
Etoricoxib—Nausea—Lovastatin—atherosclerosis	0.000173	0.001	CcSEcCtD
Etoricoxib—Rash—Simvastatin—atherosclerosis	0.000172	0.000998	CcSEcCtD
Etoricoxib—Dermatitis—Simvastatin—atherosclerosis	0.000172	0.000997	CcSEcCtD
Etoricoxib—Diarrhoea—Niacin—atherosclerosis	0.000171	0.000994	CcSEcCtD
Etoricoxib—Headache—Simvastatin—atherosclerosis	0.000171	0.000991	CcSEcCtD
Etoricoxib—Nausea—Ezetimibe—atherosclerosis	0.00017	0.000986	CcSEcCtD
Etoricoxib—Diarrhoea—Pravastatin—atherosclerosis	0.000169	0.000979	CcSEcCtD
Etoricoxib—Dizziness—Niacin—atherosclerosis	0.000166	0.000961	CcSEcCtD
Etoricoxib—Dizziness—Pravastatin—atherosclerosis	0.000163	0.000946	CcSEcCtD
Etoricoxib—Nausea—Simvastatin—atherosclerosis	0.000162	0.00094	CcSEcCtD
Etoricoxib—Vomiting—Niacin—atherosclerosis	0.000159	0.000924	CcSEcCtD
Etoricoxib—Rash—Niacin—atherosclerosis	0.000158	0.000916	CcSEcCtD
Etoricoxib—Dermatitis—Niacin—atherosclerosis	0.000158	0.000915	CcSEcCtD
Etoricoxib—Headache—Niacin—atherosclerosis	0.000157	0.00091	CcSEcCtD
Etoricoxib—Vomiting—Pravastatin—atherosclerosis	0.000157	0.00091	CcSEcCtD
Etoricoxib—Rash—Pravastatin—atherosclerosis	0.000156	0.000902	CcSEcCtD
Etoricoxib—Dermatitis—Pravastatin—atherosclerosis	0.000155	0.000901	CcSEcCtD
Etoricoxib—Headache—Pravastatin—atherosclerosis	0.000155	0.000896	CcSEcCtD
Etoricoxib—CYP3A4—liver—atherosclerosis	0.000154	0.0104	CbGeAlD
Etoricoxib—CYP2D6—liver—atherosclerosis	0.000151	0.0102	CbGeAlD
Etoricoxib—Nausea—Niacin—atherosclerosis	0.000149	0.000863	CcSEcCtD
Etoricoxib—Nausea—Pravastatin—atherosclerosis	0.000146	0.00085	CcSEcCtD
Etoricoxib—CYP1A2—Metabolism—BGN—atherosclerosis	9.82e-06	7.95e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	9.77e-06	7.91e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	9.75e-06	7.89e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AGT—atherosclerosis	9.73e-06	7.87e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—APOA5—atherosclerosis	9.72e-06	7.87e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—FABP4—atherosclerosis	9.71e-06	7.86e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—LCAT—atherosclerosis	9.71e-06	7.86e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—AKT1—atherosclerosis	9.68e-06	7.84e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—NAMPT—atherosclerosis	9.57e-06	7.75e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—SCARB1—atherosclerosis	9.55e-06	7.73e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—LEP—atherosclerosis	9.53e-06	7.71e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—APOE—atherosclerosis	9.53e-06	7.71e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—APOA4—atherosclerosis	9.53e-06	7.71e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—LIPC—atherosclerosis	9.51e-06	7.7e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—HMOX1—atherosclerosis	9.5e-06	7.69e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—NAMPT—atherosclerosis	9.49e-06	7.68e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—APOC3—atherosclerosis	9.45e-06	7.65e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—IL6—atherosclerosis	9.45e-06	7.65e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	9.45e-06	7.64e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CAV1—atherosclerosis	9.45e-06	7.64e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	9.43e-06	7.63e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—LIPC—atherosclerosis	9.43e-06	7.63e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—APOA1—atherosclerosis	9.42e-06	7.63e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL1B—atherosclerosis	9.4e-06	7.61e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—LDLR—atherosclerosis	9.4e-06	7.6e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—APOC3—atherosclerosis	9.37e-06	7.58e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP7A1—atherosclerosis	9.36e-06	7.58e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PLA2G1B—atherosclerosis	9.36e-06	7.57e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MTHFR—atherosclerosis	9.34e-06	7.56e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—LDLR—atherosclerosis	9.31e-06	7.54e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	9.3e-06	7.53e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	9.26e-06	7.49e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CETP—atherosclerosis	9.18e-06	7.43e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	9.17e-06	7.42e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	9.15e-06	7.4e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—ESR1—atherosclerosis	9.1e-06	7.37e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—APOB—atherosclerosis	9.1e-06	7.36e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CETP—atherosclerosis	9.1e-06	7.36e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PDGFB—atherosclerosis	9.09e-06	7.36e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ALOX5—atherosclerosis	9.04e-06	7.32e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—HMGCR—atherosclerosis	9.02e-06	7.3e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—F2—atherosclerosis	8.99e-06	7.28e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—HMOX1—atherosclerosis	8.94e-06	7.24e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GSTM1—atherosclerosis	8.85e-06	7.16e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—SCARB1—atherosclerosis	8.79e-06	7.11e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—NFKB1—atherosclerosis	8.77e-06	7.1e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—AKT1—atherosclerosis	8.72e-06	7.06e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—SCARB1—atherosclerosis	8.71e-06	7.05e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—APOE—atherosclerosis	8.7e-06	7.04e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—LPL—atherosclerosis	8.69e-06	7.03e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP27A1—atherosclerosis	8.66e-06	7e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—MAPK8—atherosclerosis	8.62e-06	6.98e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CAV1—atherosclerosis	8.62e-06	6.97e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CG—atherosclerosis	8.6e-06	6.96e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—APOA1—atherosclerosis	8.6e-06	6.96e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—APOB—atherosclerosis	8.57e-06	6.93e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	8.48e-06	6.86e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GPX1—atherosclerosis	8.48e-06	6.86e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	8.35e-06	6.76e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GSTM1—atherosclerosis	8.33e-06	6.74e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—HMGCR—atherosclerosis	8.3e-06	6.72e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CD36—atherosclerosis	8.26e-06	6.68e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—HMGCR—atherosclerosis	8.23e-06	6.66e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	8.21e-06	6.64e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	8.21e-06	6.64e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ALOX15—atherosclerosis	8.21e-06	6.64e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—APOA2—atherosclerosis	8.21e-06	6.64e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—LPL—atherosclerosis	8.18e-06	6.62e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—INS—atherosclerosis	8.14e-06	6.59e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	8.14e-06	6.59e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NAMPT—atherosclerosis	8.11e-06	6.56e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ABCG5—atherosclerosis	8.11e-06	6.56e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NOS2—atherosclerosis	8.1e-06	6.56e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	8.06e-06	6.52e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—LIPC—atherosclerosis	8.06e-06	6.52e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ABCA1—atherosclerosis	8.04e-06	6.51e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCL2—atherosclerosis	8.01e-06	6.48e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—APOC3—atherosclerosis	8.01e-06	6.48e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GPX1—atherosclerosis	7.98e-06	6.46e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—LDLR—atherosclerosis	7.96e-06	6.44e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—STAT3—atherosclerosis	7.88e-06	6.38e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IGF1—atherosclerosis	7.88e-06	6.37e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—LPA—atherosclerosis	7.83e-06	6.33e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—MTHFR—atherosclerosis	7.82e-06	6.33e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CETP—atherosclerosis	7.77e-06	6.29e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CD36—atherosclerosis	7.77e-06	6.29e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PPARA—atherosclerosis	7.68e-06	6.21e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—BGN—atherosclerosis	7.58e-06	6.14e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—MAPK3—atherosclerosis	7.53e-06	6.09e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—APOA5—atherosclerosis	7.51e-06	6.07e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—MAPK3—atherosclerosis	7.49e-06	6.06e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—SERPINE1—atherosclerosis	7.48e-06	6.05e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—SCARB1—atherosclerosis	7.44e-06	6.02e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—AGT—atherosclerosis	7.43e-06	6.02e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—INS—atherosclerosis	7.43e-06	6.01e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	7.42e-06	6.01e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ABCA1—atherosclerosis	7.4e-06	5.99e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—MTHFR—atherosclerosis	7.36e-06	5.96e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ABCA1—atherosclerosis	7.33e-06	5.93e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—APOE—atherosclerosis	7.28e-06	5.89e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	7.25e-06	5.87e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PPARA—atherosclerosis	7.23e-06	5.85e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	7.22e-06	5.85e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CAV1—atherosclerosis	7.22e-06	5.84e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—APOA1—atherosclerosis	7.2e-06	5.83e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NOS3—atherosclerosis	7.14e-06	5.78e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—HMGCR—atherosclerosis	7.03e-06	5.69e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—AGT—atherosclerosis	7e-06	5.66e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ALOX5—atherosclerosis	6.98e-06	5.65e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—HMOX1—atherosclerosis	6.9e-06	5.58e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—APOE—atherosclerosis	6.86e-06	5.55e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—SERPINE1—atherosclerosis	6.82e-06	5.52e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CAV1—atherosclerosis	6.79e-06	5.5e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—APOA1—atherosclerosis	6.78e-06	5.48e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—APOB—atherosclerosis	6.61e-06	5.35e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CG—atherosclerosis	6.57e-06	5.32e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NOS3—atherosclerosis	6.52e-06	5.27e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GSTM1—atherosclerosis	6.43e-06	5.2e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—HMOX1—atherosclerosis	6.35e-06	5.14e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PPARG—atherosclerosis	6.34e-06	5.13e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	6.34e-06	5.13e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CXCL8—atherosclerosis	6.34e-06	5.13e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—LPL—atherosclerosis	6.31e-06	5.11e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—HMOX1—atherosclerosis	6.29e-06	5.09e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ABCA1—atherosclerosis	6.27e-06	5.07e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NAMPT—atherosclerosis	6.26e-06	5.06e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—INS—atherosclerosis	6.22e-06	5.04e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—LIPC—atherosclerosis	6.22e-06	5.03e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CG—atherosclerosis	6.19e-06	5.01e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—APOC3—atherosclerosis	6.18e-06	5e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GPX1—atherosclerosis	6.16e-06	4.98e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—LDLR—atherosclerosis	6.14e-06	4.97e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—APOB—atherosclerosis	6.08e-06	4.92e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—APOB—atherosclerosis	6.03e-06	4.88e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CETP—atherosclerosis	6e-06	4.86e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CD36—atherosclerosis	6e-06	4.85e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PPARG—atherosclerosis	5.97e-06	4.83e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GSTM1—atherosclerosis	5.91e-06	4.79e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GSTM1—atherosclerosis	5.86e-06	4.74e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—INS—atherosclerosis	5.86e-06	4.74e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—LPL—atherosclerosis	5.8e-06	4.7e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—LPL—atherosclerosis	5.75e-06	4.66e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SCARB1—atherosclerosis	5.75e-06	4.65e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MMP9—atherosclerosis	5.73e-06	4.64e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ALB—atherosclerosis	5.7e-06	4.62e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—MTHFR—atherosclerosis	5.68e-06	4.6e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NFKB1—atherosclerosis	5.67e-06	4.59e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GPX1—atherosclerosis	5.66e-06	4.58e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GPX1—atherosclerosis	5.61e-06	4.54e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PPARA—atherosclerosis	5.57e-06	4.51e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MAPK8—atherosclerosis	5.57e-06	4.51e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CD36—atherosclerosis	5.52e-06	4.46e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL6—atherosclerosis	5.5e-06	4.45e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CD36—atherosclerosis	5.47e-06	4.42e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—NOS3—atherosclerosis	5.46e-06	4.42e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—HMGCR—atherosclerosis	5.43e-06	4.39e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—AGT—atherosclerosis	5.4e-06	4.37e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—HMOX1—atherosclerosis	5.38e-06	4.35e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ALB—atherosclerosis	5.37e-06	4.35e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—APOE—atherosclerosis	5.29e-06	4.28e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CAV1—atherosclerosis	5.24e-06	4.24e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—APOA1—atherosclerosis	5.23e-06	4.23e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—MTHFR—atherosclerosis	5.23e-06	4.23e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—MTHFR—atherosclerosis	5.18e-06	4.19e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—APOB—atherosclerosis	5.15e-06	4.17e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—VEGFA—atherosclerosis	5.15e-06	4.16e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—NOS3—atherosclerosis	5.14e-06	4.16e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PPARA—atherosclerosis	5.13e-06	4.15e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—STAT3—atherosclerosis	5.09e-06	4.12e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PPARA—atherosclerosis	5.08e-06	4.11e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—AKT1—atherosclerosis	5.08e-06	4.11e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—AKT1—atherosclerosis	5.05e-06	4.09e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTM1—atherosclerosis	5.01e-06	4.05e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—AGT—atherosclerosis	4.97e-06	4.02e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—AGT—atherosclerosis	4.92e-06	3.98e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—LPL—atherosclerosis	4.92e-06	3.98e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MAPK3—atherosclerosis	4.87e-06	3.94e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—APOE—atherosclerosis	4.87e-06	3.94e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ABCA1—atherosclerosis	4.84e-06	3.91e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—APOE—atherosclerosis	4.82e-06	3.9e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CAV1—atherosclerosis	4.82e-06	3.9e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—APOA1—atherosclerosis	4.81e-06	3.89e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GPX1—atherosclerosis	4.8e-06	3.88e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CAV1—atherosclerosis	4.78e-06	3.87e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CG—atherosclerosis	4.77e-06	3.86e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—APOA1—atherosclerosis	4.77e-06	3.86e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TGFB1—atherosclerosis	4.72e-06	3.82e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PTGS2—atherosclerosis	4.7e-06	3.8e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CD36—atherosclerosis	4.67e-06	3.78e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—STAT3—atherosclerosis	4.65e-06	3.76e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PPARG—atherosclerosis	4.61e-06	3.73e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—INS—atherosclerosis	4.52e-06	3.66e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MAPK3—atherosclerosis	4.44e-06	3.59e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—MTHFR—atherosclerosis	4.43e-06	3.58e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CG—atherosclerosis	4.39e-06	3.55e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CG—atherosclerosis	4.35e-06	3.52e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PPARA—atherosclerosis	4.34e-06	3.51e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TGFB1—atherosclerosis	4.31e-06	3.49e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PPARG—atherosclerosis	4.24e-06	3.43e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—AGT—atherosclerosis	4.21e-06	3.4e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PPARG—atherosclerosis	4.2e-06	3.4e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—INS—atherosclerosis	4.16e-06	3.36e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—HMOX1—atherosclerosis	4.15e-06	3.36e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ALB—atherosclerosis	4.14e-06	3.35e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—APOE—atherosclerosis	4.12e-06	3.34e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—INS—atherosclerosis	4.12e-06	3.33e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CAV1—atherosclerosis	4.08e-06	3.3e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—APOA1—atherosclerosis	4.07e-06	3.3e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—APOB—atherosclerosis	3.97e-06	3.22e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—NOS3—atherosclerosis	3.96e-06	3.21e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTM1—atherosclerosis	3.87e-06	3.13e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ALB—atherosclerosis	3.81e-06	3.08e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—LPL—atherosclerosis	3.8e-06	3.07e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ALB—atherosclerosis	3.78e-06	3.06e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CG—atherosclerosis	3.72e-06	3.01e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GPX1—atherosclerosis	3.7e-06	3e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—NOS3—atherosclerosis	3.65e-06	2.95e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTGS2—atherosclerosis	3.62e-06	2.93e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—NOS3—atherosclerosis	3.61e-06	2.92e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CD36—atherosclerosis	3.61e-06	2.92e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PPARG—atherosclerosis	3.59e-06	2.91e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL6—atherosclerosis	3.56e-06	2.88e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—INS—atherosclerosis	3.52e-06	2.85e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.42e-06	2.76e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PPARA—atherosclerosis	3.35e-06	2.71e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTGS2—atherosclerosis	3.33e-06	2.7e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTGS2—atherosclerosis	3.31e-06	2.67e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AKT1—atherosclerosis	3.28e-06	2.66e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—AGT—atherosclerosis	3.25e-06	2.63e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—IL6—atherosclerosis	3.25e-06	2.63e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ALB—atherosclerosis	3.23e-06	2.61e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—APOE—atherosclerosis	3.18e-06	2.57e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CAV1—atherosclerosis	3.15e-06	2.55e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—APOA1—atherosclerosis	3.14e-06	2.54e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NOS3—atherosclerosis	3.09e-06	2.5e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—AKT1—atherosclerosis	3e-06	2.42e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.87e-06	2.32e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTGS2—atherosclerosis	2.82e-06	2.29e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PPARG—atherosclerosis	2.77e-06	2.24e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—INS—atherosclerosis	2.72e-06	2.2e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—AKT1—atherosclerosis	2.51e-06	2.03e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ALB—atherosclerosis	2.49e-06	2.02e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NOS3—atherosclerosis	2.38e-06	1.93e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—AKT1—atherosclerosis	2.36e-06	1.91e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.18e-06	1.76e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—AKT1—atherosclerosis	1.82e-06	1.47e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—AKT1—atherosclerosis	1.68e-06	1.36e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—AKT1—atherosclerosis	1.66e-06	1.34e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—AKT1—atherosclerosis	1.42e-06	1.15e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—AKT1—atherosclerosis	1.1e-06	8.86e-06	CbGpPWpGaD
